1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Bio-Techne entered a merger agreement under which Merck KGaA's subsidiary will merge into the company, leaving Bio-Techne as a wholly-owned Merck KGaA subsidiary. Each share will convert into the right to receive $73.00 in cash, and the board has recommended that shareholders approve the deal.
Merger consideration: $73.00 in cash per share of common stock, less any required tax withholdings
Buyer: Merck KGaA, Darmstadt, Germany, through its subsidiary EMD Holdings NewCo, Inc.
Closing requires majority shareholder approval, expiration of the Hart-Scott-Rodino waiting period and other required approvals, and no Burdensome Condition
onsemi agreed to acquire Synaptics in an all-stock transaction with a total enterprise value of approximately $7 billion. Each Synaptics share will convert into 1.350 onsemi shares, a premium of approximately 19% to the 10-day volume weighted average closing prices, and Synaptics stockholders are expected to own about 12% of the combined company. Closing is expected in mid-2027, subject to a Synaptics stockholder vote, regulatory approvals and other conditions, and Synaptics agreed to pay onsemi a $235 million termination fee in specified circumstances.
Each Synaptics share converts into 1.350 shares of onsemi common stock; the deal is all-stock
Total enterprise value of approximately $7 billion, about a 19% premium to 10-day VWAP
Expected close in mid-2027; the End Date is June 25, 2027, extendable up to 21 months
Synaptics termination fee of $235 million; onsemi regulatory termination fee of $320 million
H.B. Fuller reported second quarter 2026 net revenue of $950 million, up 5.8% year-on-year, and diluted EPS of $1.23 versus $0.76 a year earlier. The company raised the midpoint of its full-year adjusted EBITDA and adjusted EPS guidance, which matters to shareholders because it points to stronger expected profit for fiscal 2026.
Net revenue of $950 million, up 5.8%; organic revenue up 2.6% year-on-year
Diluted EPS of $1.23 versus $0.76 a year earlier; adjusted diluted EPS of $1.41, up 19%
Fiscal 2026 adjusted EBITDA now expected at $650 million to $675 million; adjusted EPS at $4.60 to $4.90
Record second quarter operating cash flow of $121 million; 750 thousand shares repurchased in the quarter
CMC reported fiscal third-quarter 2026 results for the period ended May 31, 2026, with net sales of $2.48 billion, up 22.9% from a year earlier. Net earnings were $173.0 million, or $1.55 per diluted share, compared with $83.1 million, or $0.73 per share, a year earlier, and core EBITDA rose 78.6% to $353.6 million. The company also declared a $0.20 quarterly dividend and said it expects core EBITDA to increase sequentially in the fourth quarter.
Net sales were $2.48 billion, up 22.9% year over year from $2.02 billion.
Net earnings were $173.0 million, or $1.55 per diluted share, versus $0.73 per diluted share a year earlier; adjusted earnings were $1.73 per diluted share.
Core EBITDA rose 78.6% to $353.6 million, with a 14.2% margin; the company cited the recent precast acquisitions and stronger metal margins.
A quarterly dividend of $0.20 per share is payable July 15, 2026, and CMC will host an Investor Day on August 5, 2026.
Acuity reported fiscal third-quarter results for the quarter ended May 31, 2026, with net sales of $1.2 billion, up 1.6% from a year earlier. GAAP diluted EPS rose 46.2% to $4.56, and adjusted diluted EPS rose 3.7% to $5.31, while adjusted operating profit grew only 0.8%. The release does not include updated guidance.
Net sales were $1,198.0 million, up $19.4 million or 1.6% from $1,178.6 million in the prior-year quarter.
Diluted EPS was $4.56 versus $3.12 a year earlier; adjusted diluted EPS was $5.31 versus $5.12.
Adjusted operating profit was $223.5 million, up 0.8%, with an adjusted operating margin of 18.7%, down 10 basis points.
Net cash from operating activities was $520.2 million for the first nine months of fiscal 2026; the company repurchased about 766,000 shares for $230 million year to date.
Darden reported fiscal fourth-quarter sales of $3.72 billion, up 13.7%, with adjusted diluted earnings per share from continuing operations of $3.66, up 22.8%; the quarter included an extra week that contributed $0.25 per share. The company also raised its quarterly dividend to $1.62 per share, authorized a new $1.5 billion share repurchase program, and issued fiscal 2027 guidance for diluted earnings per share from continuing operations of $11.10 to $11.35.
Q4 sales rose 13.7% to $3.72 billion, including 7.6 percentage points from the extra week; blended same-restaurant sales rose 4.6%
Fiscal 2027 outlook: total sales of $13.60 billion to $13.75 billion and diluted EPS from continuing operations of $11.10 to $11.35
Quarterly dividend increased 8.0% to $1.62 per share, payable August 3, 2026 to holders of record on July 10, 2026
Board amended bylaws effective immediately, raising the shareholder aggregation limit for director nominations from 10 to 20 shareholders
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.